Maria Josephina T Gomez, NP
Nurse Practitioner · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 25 years
- Graduated 2001
Offices
1 location · Regents of the University of California · 706 clinicians in this group
Looking this up.
Hospitals listed: Marinhealth Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Maria Josephina T Gomez’s office at (415) 476-4029 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$18,987
Medicare paid this office $18,987 for 128 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 74 | $9,555 | $102 |
| Return visit (30+ min) | 44 | $4,143 | $71 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 103 | $2,002 | $12 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $889 | $64 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $749 | $44 |
See all 6 services
| Long return visit (40+ min) | 74 | $9,555 | $102 |
| Return visit (30+ min) | 44 | $4,143 | $71 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 103 | $2,002 | $12 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $889 | $64 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $749 | $44 |
| Short return visit (20+ min) | 16 | $629 | $39 |
Who their Medicare patients are
128 Original Medicare patients in 2024. Average age 68 · Under 65 29% · 85 and older 11% · Women 67% · Also on Medicaid 39% · Health risk score 1.88. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 62% · Chronic kidney disease 30% · Depression 29% · Diabetes 23% · Coronary heart disease 20% · Cancer 16% · COPD 16% · Heart failure 15% · Atrial fibrillation 15% · Dementia 11% · Stroke 11%.
The office billed $158,508, Medicare allowed $25,425 and paid $18,987; for 427 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 128 | 427 | 68 | 1.88 | $158,508 | $18,987 |
| 2023 | 120 | 809 | 68 | 2.24 | $169,503 | $24,345 |
| 2022 | 95 | 134 | 68 | 1.67 | $75,438 | $10,298 |
| 2021 | 74 | 137 | 68 | 1.77 | $82,575 | $11,823 |
| 2020 | 53 | 73 | 67 | 1.36 | $42,867 | $4,894 |
| 2019 | 47 | 65 | 67 | 1.53 | $39,109 | $3,794 |
| 2018 | 38 | 51 | 67 | 1.46 | $31,550 | $3,421 |
| 2017 | 37 | 38 | 66 | 1.89 | $9,778 | $1,824 |
| 2016 | 83 | 107 | 67 | 1.88 | $13,783 | $4,691 |
| 2015 | 71 | 82 | 67 | 1.72 | $13,918 | $4,136 |
| 2014 | 24 | 29 | 70 | 1.59 | $3,886 | $1,146 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Long return visit (40+ min) | 76 | $11,142 | $103 |
| Return visit (30+ min) | 42 | $3,454 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $973 | $75 |
| Short return visit (20+ min) | 12 | $609 | $47 |
2022: 3 services
| Long return visit (40+ min) | 44 | $5,019 | $102 |
| Return visit (30+ min) | 37 | $3,517 | $72 |
| Short return visit (20+ min) | 13 | $574 | $44 |
2021: 3 services
| Long return visit (40+ min) | 54 | $8,080 | $105 |
| Return visit (30+ min) | 20 | $1,835 | $71 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,171 | $65 |
2020: 2 services
| Long return visit (40+ min) | 28 | $2,752 | $81 |
| Return visit (30+ min) | 14 | $906 | $57 |
2019: 2 services
| Return visit (30+ min) | 22 | $1,811 | $57 |
| Long return visit (40+ min) | 19 | $1,555 | $74 |
2018: 2 services
| Long return visit (40+ min) | 22 | $2,081 | $80 |
| Return visit (30+ min) | 17 | $1,069 | $59 |
2017: 1 service
| Short return visit (20+ min) | 11 | $349 | $32 |
2016: 4 services
| Return visit (30+ min) | 26 | $1,607 | $57 |
| Short return visit (20+ min) | 33 | $1,433 | $39 |
| Long return visit (40+ min) | 11 | $926 | $84 |
| Short return visit | 19 | $379 | $17 |
2015: 2 services
| Return visit (30+ min) | 24 | $1,489 | $57 |
| Short return visit (20+ min) | 27 | $1,083 | $37 |
Drugs they prescribed that Part D paid
$4,801,154
Pharmacies billed $4,801,154 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,595) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
1,825 generic and 757 brand-name prescriptions · $4,801,154 in drug cost · 66 antibiotic prescriptions to 41 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 102 | $2,562,471 | $25,122 |
| Gattex | 19 | $878,179 | $46,220 |
| Skyrizi on-Body | 15 | $279,471 | $18,631 |
| Humira(Cf) | 25 | $210,794 | $8,432 |
| Creon | 41 | $103,794 | $2,532 |
See all 41 drugs
| Stelara | 102 | $2,562,471 | $25,122 |
| Gattex | 19 | $878,179 | $46,220 |
| Skyrizi on-Body | 15 | $279,471 | $18,631 |
| Humira(Cf) | 25 | $210,794 | $8,432 |
| Creon | 41 | $103,794 | $2,532 |
| Entyvio | 12 | $97,212 | $8,101 |
| Xifaxan | 30 | $72,225 | $2,408 |
| Motegrity | 89 | $67,566 | $759 |
| Linzess | 92 | $66,787 | $726 |
| Pertzye | 12 | $66,406 | $5,534 |
| Mytesi | 15 | $43,902 | $2,927 |
| Zenpep | 16 | $38,067 | $2,379 |
| Lotronex | 13 | $32,525 | $2,502 |
| Mesalamine | 24 | $17,963 | $748 |
| Trulance | 18 | $9,054 | $503 |
| Gavilyte-G | 399 | $6,677 | $17 |
| Dexlansoprazole Dr | 20 | $5,814 | $291 |
| Lansoprazole | 17 | $5,265 | $310 |
| Sucralfate | 53 | $4,886 | $92 |
| Lubiprostone | 33 | $4,038 | $122 |
| Sod Sulf-Potass Sulf-Mag Sulf | 51 | $3,459 | $68 |
| Omeprazole | 196 | $3,301 | $17 |
| Diphenoxylate-Atropine | 44 | $1,958 | $44 |
| Peg-3350 and Electrolytes | 112 | $1,838 | $16 |
| Budesonide Dr | 12 | $1,823 | $152 |
| Pantoprazole | 94 | $1,255 | $13 |
| Ondansetron | 519 | $1,088 | $2 |
| Colesevelam | 12 | $972 | $81 |
| Famotidine | 95 | $879 | $9 |
| Gavilyte-C | 53 | $873 | $16 |
| Hydrocortisone | 12 | $846 | $71 |
| Dicyclomine | 29 | $539 | $19 |
| Ursodiol | 14 | $411 | $29 |
| Mirtazapine | 13 | $403 | $31 |
| Esomeprazole Magnesium | 14 | $362 | $26 |
| Ondansetron Odt | 18 | $351 | $19 |
| Gabapentin | 18 | $346 | $19 |
| Methotrexate | 11 | $158 | $14 |
| Metronidazole | 16 | $136 | $9 |
| Nortriptyline | 15 | $97 | $6 |
| Metformin | 11 | $42 | $4 |
Year by year
| 2024 | 2,595 | 924 | 0% (0) | 29% | $4,801,154 |
| 2023 | 2,590 | 918 | None | None | $5,351,183 |
| 2022 | 2,577 | 1,051 | None | None | $5,776,613 |
| 2021 | 1,521 | 732 | None | None | $1,770,283 |
| 2020 | 1,596 | 678 | None | None | $2,258,943 |
| 2019 | 1,277 | 517 | None | None | $1,599,160 |
| 2018 | 1,034 | 390 | 0% (0) | None | $959,882 |
| 2017 | 660 | 247 | None | 28% | $359,622 |
| 2016 | 495 | 132 | None | 35% | $239,525 |
| 2015 | 329 | 88 | None | 29% | $135,615 |
| 2014 | 274 | 87 | None | 30% | $91,339 |
| 2013 | 184 | 77 | None | 31% | $35,949 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Stelara | 99 | $2,710,190 | $27,376 |
| Gattex | 27 | $1,210,480 | $44,833 |
| Humira(Cf) | 40 | $364,032 | $9,101 |
| Creon | 61 | $193,198 | $3,167 |
| Xifaxan | 61 | $140,124 | $2,297 |
| Pertzye | 14 | $69,032 | $4,931 |
| Linzess | 61 | $45,924 | $753 |
| Motegrity | 60 | $41,869 | $698 |
| Lotronex | 14 | $36,497 | $2,607 |
| Mytesi | 14 | $35,031 | $2,502 |
| Mesalamine | 29 | $28,915 | $997 |
| Dexlansoprazole Dr | 28 | $11,953 | $427 |
| Gavilyte-G | 508 | $9,440 | $19 |
| Colesevelam | 19 | $8,650 | $455 |
| Lubiprostone | 15 | $7,150 | $477 |
| Lansoprazole | 14 | $5,563 | $397 |
| Dexilant | 11 | $5,355 | $487 |
| Omeprazole | 214 | $4,881 | $23 |
| Sucralfate | 41 | $3,111 | $76 |
| Sod Sulf-Potass Sulf-Mag Sulf | 35 | $2,782 | $79 |
| Famotidine | 127 | $2,572 | $20 |
| Pantoprazole | 94 | $2,045 | $22 |
| Diphenoxylate-Atropine | 32 | $1,905 | $60 |
| Ondansetron | 513 | $1,890 | $4 |
| Loperamide | 11 | $997 | $91 |
| Peg-3350 and Electrolytes | 48 | $976 | $20 |
| Dicyclomine | 30 | $941 | $31 |
| Ondansetron Odt | 21 | $598 | $28 |
| Esomeprazole Magnesium | 12 | $523 | $44 |
| Desipramine | 13 | $504 | $39 |
| Gavilyte-C | 26 | $468 | $18 |
| Gabapentin | 17 | $434 | $26 |
| Mirtazapine | 24 | $422 | $18 |
| Methotrexate | 11 | $172 | $16 |
| Nortriptyline | 13 | $106 | $8 |
| Prochlorperazine Maleate | 12 | $61 | $5 |
2022: 35 drugs
| Stelara | 155 | $4,254,022 | $27,445 |
| Humira(Cf) | 48 | $413,073 | $8,606 |
| Creon | 65 | $139,232 | $2,142 |
| Xifaxan | 65 | $133,665 | $2,056 |
| Xeljanz | 11 | $77,045 | $7,004 |
| Pertzye | 12 | $56,328 | $4,694 |
| Mesalamine | 35 | $45,229 | $1,292 |
| Budesonide Er | 19 | $37,986 | $1,999 |
| Linzess | 53 | $35,491 | $670 |
| Motegrity | 25 | $16,355 | $654 |
| Dexilant | 23 | $15,840 | $689 |
| Lubiprostone | 12 | $6,292 | $524 |
| Gavilyte-G | 311 | $4,819 | $15 |
| Omeprazole | 191 | $4,548 | $24 |
| Peg-3350 and Electrolytes | 336 | $4,533 | $13 |
| Suprep | 37 | $4,434 | $120 |
| Colestipol | 20 | $3,169 | $158 |
| Ondansetron | 439 | $2,332 | $5 |
| Sucralfate | 22 | $2,162 | $98 |
| Pantoprazole | 89 | $2,149 | $24 |
| Famotidine | 102 | $1,921 | $19 |
| Diphenoxylate-Atropine | 21 | $1,396 | $66 |
| Dicyclomine | 49 | $1,350 | $28 |
| Hydrocortisone | 16 | $1,204 | $75 |
| Sod Sulf-Potass Sulf-Mag Sulf | 14 | $1,186 | $85 |
| Lansoprazole | 14 | $914 | $65 |
| Amoxicillin-Clavulanate Potass | 14 | $786 | $56 |
| Loperamide | 11 | $556 | $51 |
| Peg 3350-Electrolyte | 29 | $554 | $19 |
| Gavilyte-C | 16 | $314 | $20 |
| Golytely | 11 | $204 | $19 |
| Mirtazapine | 15 | $197 | $13 |
| Prednisone | 14 | $176 | $13 |
| Metronidazole | 15 | $154 | $10 |
| Prochlorperazine Maleate | 17 | $39 | $2 |
2021: 27 drugs
| Stelara | 47 | $1,149,550 | $24,459 |
| Humira(Cf) | 28 | $269,748 | $9,634 |
| Creon | 56 | $134,727 | $2,406 |
| Xifaxan | 24 | $44,627 | $1,859 |
| Mesalamine | 23 | $21,845 | $950 |
| Linzess | 15 | $12,997 | $866 |
| Suprep | 101 | $11,247 | $111 |
| Dexilant | 17 | $9,678 | $569 |
| Amitiza | 24 | $9,164 | $382 |
| Peg-3350 and Electrolytes | 246 | $3,134 | $13 |
| Plenvu | 20 | $2,858 | $143 |
| Sucralfate | 20 | $2,669 | $133 |
| Clenpiq | 14 | $2,276 | $163 |
| Omeprazole | 97 | $2,140 | $22 |
| Esomeprazole Magnesium | 16 | $1,980 | $124 |
| Budesonide Dr | 11 | $1,926 | $175 |
| Pantoprazole | 59 | $1,581 | $27 |
| Famotidine | 75 | $1,344 | $18 |
| Lansoprazole | 16 | $1,180 | $74 |
| Gavilyte-G | 91 | $1,147 | $13 |
| Dicyclomine | 30 | $1,058 | $35 |
| Diphenoxylate-Atropine | 16 | $823 | $51 |
| Ondansetron | 224 | $821 | $4 |
| Peg 3350-Electrolyte | 36 | $553 | $15 |
| Prednisone | 11 | $218 | $20 |
| Mirtazapine | 11 | $145 | $13 |
| Metronidazole | 14 | $104 | $7 |
2020: 26 drugs
| Stelara | 44 | $1,017,190 | $23,118 |
| Humira(Cf) | 49 | $369,977 | $7,551 |
| Creon | 64 | $175,876 | $2,748 |
| Cimzia | 26 | $168,776 | $6,491 |
| Xifaxan | 32 | $59,933 | $1,873 |
| Mesalamine | 64 | $47,952 | $749 |
| Viberzi | 12 | $27,242 | $2,270 |
| Dexilant | 39 | $17,239 | $442 |
| Amitiza | 26 | $14,474 | $557 |
| Linzess | 26 | $14,437 | $555 |
| Budesonide Ec | 21 | $9,564 | $455 |
| Gavilyte-G | 252 | $3,380 | $13 |
| Suprep | 30 | $3,178 | $106 |
| Colestipol | 11 | $2,517 | $229 |
| Omeprazole | 97 | $1,671 | $17 |
| Esomeprazole Magnesium | 17 | $1,641 | $97 |
| Famotidine | 72 | $1,594 | $22 |
| Sucralfate | 24 | $1,450 | $60 |
| Peg-3350 and Electrolytes | 96 | $1,245 | $13 |
| Desipramine | 15 | $1,052 | $70 |
| Dicyclomine | 33 | $1,019 | $31 |
| Pantoprazole | 59 | $885 | $15 |
| Ondansetron | 217 | $834 | $4 |
| Methotrexate | 12 | $566 | $47 |
| Diphenoxylate-Atropine | 12 | $541 | $45 |
| Lansoprazole | 15 | $343 | $23 |
2019: 31 drugs
| Stelara | 26 | $582,394 | $22,400 |
| Humira(Cf) | 28 | $237,865 | $8,495 |
| Humira | 24 | $176,434 | $7,351 |
| Humira | 14 | $154,737 | $11,053 |
| Creon | 42 | $125,687 | $2,993 |
| Cimzia | 12 | $69,560 | $5,797 |
| Mesalamine | 74 | $62,158 | $840 |
| Xeljanz | 12 | $49,771 | $4,148 |
| Xifaxan | 16 | $27,620 | $1,726 |
| Budesonide Ec | 33 | $15,649 | $474 |
| Apriso | 12 | $9,392 | $783 |
| Welchol | 11 | $7,383 | $671 |
| Linzess | 13 | $5,694 | $438 |
| Amitiza | 11 | $5,089 | $463 |
| Gavilyte-G | 282 | $4,078 | $14 |
| Suprep | 31 | $3,076 | $99 |
| Omeprazole | 79 | $1,244 | $16 |
| Azathioprine | 14 | $1,205 | $86 |
| Ondansetron Odt | 11 | $1,185 | $108 |
| Esomeprazole Magnesium | 12 | $1,059 | $88 |
| Methotrexate | 27 | $821 | $30 |
| Pantoprazole | 40 | $812 | $20 |
| Dicyclomine | 25 | $648 | $26 |
| Diphenoxylate-Atropine | 13 | $428 | $33 |
| Ondansetron | 205 | $364 | $2 |
| Peg-3350 and Electrolytes | 29 | $362 | $12 |
| Famotidine | 26 | $248 | $10 |
| Peg 3350-Electrolyte | 14 | $152 | $11 |
| Ranitidine | 16 | $131 | $8 |
| Loperamide | 11 | $119 | $11 |
| Amoxicillin-Clavulanate Potass | 14 | $79 | $6 |
2018: 22 drugs
| Stelara | 16 | $327,058 | $20,441 |
| Humira | 37 | $167,912 | $4,538 |
| Xeljanz | 16 | $82,148 | $5,134 |
| Creon | 20 | $66,986 | $3,349 |
| Mesalamine | 54 | $56,404 | $1,045 |
| Budesonide Ec | 21 | $10,691 | $509 |
| Carafate | 14 | $2,708 | $193 |
| Gavilyte-G | 195 | $2,486 | $13 |
| Suprep | 25 | $2,434 | $97 |
| Moviprep | 18 | $1,917 | $106 |
| Methotrexate | 45 | $1,528 | $34 |
| Mercaptopurine | 14 | $1,358 | $97 |
| Omeprazole | 43 | $715 | $17 |
| Peg-3350 and Electrolytes | 47 | $566 | $12 |
| Pantoprazole | 27 | $430 | $16 |
| Diphenoxylate-Atropine | 16 | $312 | $19 |
| Ondansetron | 184 | $293 | $2 |
| Dicyclomine | 18 | $284 | $16 |
| Peg 3350-Electrolyte | 14 | $153 | $11 |
| Ranitidine | 24 | $117 | $5 |
| Famotidine | 13 | $82 | $6 |
| Amoxicillin-Clavulanate Potass | 12 | $69 | $6 |
2017: 17 drugs
| Creon | 40 | $82,210 | $2,055 |
| Xeljanz | 12 | $66,179 | $5,515 |
| Humira | 11 | $44,439 | $4,040 |
| Pertzye | 13 | $19,321 | $1,486 |
| Mesalamine | 14 | $14,320 | $1,023 |
| Suprep | 16 | $1,419 | $89 |
| Gavilyte-G | 91 | $1,115 | $12 |
| Polyethylene Glycol 3350 | 34 | $1,112 | $33 |
| Esomeprazole Magnesium | 11 | $1,005 | $91 |
| Methotrexate | 17 | $987 | $58 |
| Omeprazole | 45 | $563 | $13 |
| Ranitidine | 59 | $436 | $7 |
| Dicyclomine | 15 | $284 | $19 |
| Pantoprazole | 18 | $282 | $16 |
| Peg-3350 and Electrolytes | 24 | $282 | $12 |
| Diltiazem Er | 11 | $196 | $18 |
| Ondansetron | 75 | $93 | $1 |
2016: 12 drugs
| Creon | 72 | $177,789 | $2,469 |
| Pertzye | 17 | $20,626 | $1,213 |
| Dexilant | 12 | $5,299 | $442 |
| Amitiza | 13 | $4,952 | $381 |
| Polyethylene Glycol 3350 | 37 | $4,511 | $122 |
| Esomeprazole Magnesium | 12 | $1,739 | $145 |
| Gabapentin | 43 | $1,092 | $25 |
| Omeprazole | 42 | $525 | $12 |
| Ranitidine | 70 | $519 | $7 |
| Pantoprazole | 17 | $273 | $16 |
| Peg 3350-Electrolyte | 15 | $252 | $17 |
| Dicyclomine | 13 | $107 | $8 |
2015: 7 drugs
| Creon | 57 | $102,547 | $1,799 |
| Nexium | 11 | $4,472 | $407 |
| Polyethylene Glycol 3350 | 39 | $3,016 | $77 |
| Omeprazole | 42 | $502 | $12 |
| Gabapentin | 22 | $459 | $21 |
| Ranitidine | 32 | $376 | $12 |
| Pantoprazole | 12 | $179 | $15 |
2014: 7 drugs
| Creon | 31 | $34,901 | $1,126 |
| Zenpep | 14 | $30,579 | $2,184 |
| Polyethylene Glycol 3350 | 19 | $2,668 | $140 |
| Gabapentin | 17 | $563 | $33 |
| Omeprazole | 43 | $495 | $12 |
| Pantoprazole | 23 | $420 | $18 |
| Ranitidine | 22 | $392 | $18 |
2013: 5 drugs
| Creon | 16 | $17,389 | $1,087 |
| Nexium | 13 | $4,050 | $312 |
| Polyethylene Glycol 3350 | 12 | $610 | $51 |
| Pantoprazole | 14 | $285 | $20 |
| Omeprazole | 16 | $228 | $14 |
Money from drug and device companies
$535 in 2025
| 2025 | 6 | 17 | None | $535 |
| 2024 | 2 | 4 | None | $190 |
| 2023 | 2 | 6 | None | $131 |
| 2022 | 3 | 21 | None | $300 |
| 2021 | 3 | 28 | $788 | $1,288 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $147 | 8 payments
|
| Genzyme | Dupixent | $111 | 1 payment
|
| Aimmune Therapeutics | Vowst | $106 | 2 payments
|
| Celltrion USA | Vegzelma | $88 | 4 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $44 | 1 payment
|
| Ardelyx | Ibsrela | $40 | 1 payment
|
See all 17 published payments
| Celltrion USA | Meals · 2025-12-17 | Vegzelma | $35 |
| Abbvie | Meals · 2025-12-10 | Skyrizi | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-10 | Xifaxan | $44 |
| Abbvie | Meals · 2025-11-05 | Skyrizi | $31 |
| Genzyme | Meals · 2025-10-28 | Dupixent | $111 |
| Ardelyx | Meals · 2025-10-27 | Ibsrela | $40 |
| Aimmune Therapeutics | Meals · 2025-10-26 | Vowst | $42 |
| Abbvie | Meals · 2025-10-07 | Rinvoq | $21 |
| Celltrion USA | Meals · 2025-09-24 | Vegzelma | $16 |
| Abbvie | Meals · 2025-09-09 | Rinvoq | $25 |
| Celltrion USA | Meals · 2025-08-20 | Vegzelma | $22 |
| Abbvie | Meals · 2025-08-06 | Rinvoq | $15 |
| Celltrion USA | Meals · 2025-08-04 | Vegzelma | $15 |
| Aimmune Therapeutics | Meals · 2025-07-08 | Vowst | $64 |
| Abbvie | Meals · 2025-06-10 | Rinvoq | $10 |
| Abbvie | Meals · 2025-04-28 | Rinvoq | $9 |
| Abbvie | Meals · 2025-04-01 | Rinvoq | $9 |
See earlier years (2024, 2023, 2022, 2021)
2024: $190
| Lilly USA | Omvoh | $125 | 1 payment
|
| Janssen Biotech | Tremfya | $65 | 3 payments
|
2023: $131
| Janssen Biotech | Stelara | $78 | 4 payments
|
| Ironwood Pharmaceuticals | Linzess | $53 | 2 payments
|
2022: $300
| Janssen Biotech | Stelara | $241 | 17 payments
|
| Ironwood Pharmaceuticals | Linzess | $45 | 3 payments
|
| Abbvie | Linzess | $14 | 1 payment
|
2021: $1,288
| AbbVie | Skyrizi | $919 | 8 payments
|
| Janssen Biotech | Stelara | $324 | 17 payments
|
| Ironwood Pharmaceuticals | Linzess | $45 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1174670012
- Licence
- CA 443865, CA NP12784
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 300 Pasteur Drive, Stanford Hospital and Clinics, Digestive Health Center, Blake Wilbur Building, Palo Alto, CA, 94305
- NPI first listed
- 2007-01-04
- NPI last updated
- 2014-03-06
This is when the NPI record was last certified, not a medical board exam.